Dana Spigelman is an associate in Choate’s Business Department.
He assists clients in the acquisition and sale of businesses, advises on the formation and operation of private funds and represents clients in connection with public filings with the Securities and Exchange Commission.
Private Equity: represents funds of all types and aspects of capital raising and acquisitions of target companies.
Education & Credentials
- Boston University School of Law
- JD, 2017, magna cum laude
- Syracuse University
- BA, 2012
Choate represented Perceptive Xontogeny Venture Fund as the lead investor in the $35M Series A investment into AsclepiX Therapeutics, which is currently developing therapies for the treatment of diseases of the eye using novel peptides with the power to inhibit proven key disease pathways.
Choate represented Summit Partners in a growth funding round in CoderPad, a leading platform for assessing technical skills.
Choate represented Perceptive Xontogeny Venture Fund as the lead investor in the $44M Series A investment in CereVasc, a company focused on improving the treatment of patients with hydrocephalus.
Choate represented New Heritage Capital in its platform investment in Northern California-based DeWinter Group.